Marché indien des traitements contre la xérostomie – Tendances et prévisions de l’industrie jusqu’en 2030

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché indien des traitements contre la xérostomie – Tendances et prévisions de l’industrie jusqu’en 2030

  • Medical Devices
  • Publish Reports
  • Jun 2023
  • Country Level
  • 350 Pages
  • Nombre de tableaux : 22
  • Nombre de figures : 38

India Xerostomia Therapeutics Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
2024 –2030
Diagram Taille du marché (année de référence)
MILLIONS DE DOLLARS AMÉRICAINS
Diagram Taille du marché (année de prévision)
Dollars américains 25.20
Diagram TCAC
%
DiagramPrincipaux acteurs du marché
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5 < /li>

>Marché indien des thérapies contre la xérostomie, par type de produit (substituts de salive, médicaments, stylo salivaire et autres), type (vraie xérostomie et pseudo-xérostomie ou xérostomie symptomatique), mode d'achat (sur ordonnance (Rx) et en vente libre (OTC)), population (gériatrique et adultes), utilisateur final (cliniques dentaires, hôpitaux, cliniques spécialisées et soins à domicile), canal de distribution (pharmacies de détail, pharmacies hospitalières et ventes en ligne) - Tendances et prévisions de l'industrie jusqu'en 2030.

Analyse et perspectives du marché indien des thérapies contre la xérostomie

L’Inde, avec sa grande population, représente un marché important pour les produits et services de santé, y compris ceux liés à la xérostomie.

Marché indien des traitements contre la xérostomieMarché indien des traitements contre la xérostomie

Le nombre croissant de chimiothérapies et de radiothérapies et la prévalence croissante de la xérostomie devraient stimuler la croissance du marché. Les grandes entreprises élargissent leurs portefeuilles de produits dans le pays pour renforcer leur présence sur le marché de ces produits et solutions, ce qui devrait stimuler la croissance du marché. 

Le coût élevé associé au traitement de la xérostomie devrait freiner la croissance du marché. De plus, les effets secondaires associés au traitement de la xérostomie devraient freiner la croissance du marché.

Par exemple,

  • Selon une étude publiée dans le Journal of Oral Rehabilitation en 2019, la prévalence globale de la xérostomie dans la population générale était estimée à environ 10 à 20 %.

Data Bridge Market Research analyse que le marché indien des thérapies contre la xérostomie devrait atteindre la valeur de 25,20 millions USD d'ici 2030, à un TCAC de 5,1 % au cours de la période de prévision.

Rapport métrique

Détails

Période de prévision

2023 à 2030

Année de base

2022

Année historique

2021 (personnalisable de 2015 à 2020)

Unités quantitatives

Chiffre d'affaires en millions USD

Segments couverts

Type de produit (substituts de salive, médicaments, stylo salivaire et autres), type (vraie xérostomie et pseudo-xérostomie ou xérostomie symptomatique), mode d'achat (sur ordonnance (Rx) et en vente libre (OTC)), population (gériatrique et adultes), utilisateur final (cliniques dentaires, hôpitaux, cliniques spécialisées et soins à domicile), canal de distribution (pharmacies de détail, pharmacies hospitalières et ventes en ligne)

Pays couverts

Inde

Acteurs du marché couverts

Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd., Haleon Group of Companies, 3M, Alish Life Saving Impex Private Limited, GC Corporation, ICPA Health Products Ltd et Saliwell Ltd., entre autres

Définition du marché

La xérostomie, également connue sous le nom de bouche sèche, désigne un état médical caractérisé par un manque de production de salive dans la bouche. La salive joue un rôle crucial dans le maintien de la santé bucco-dentaire en humidifiant et en lubrifiant la cavité buccale, en facilitant la digestion, en neutralisant les acides et en prévenant la carie dentaire. Une quantité insuffisante de salive peut entraîner divers symptômes tels que la sécheresse, l'inconfort, la difficulté à parler, à mâcher et à avaler, une altération du goût, une mauvaise haleine et un risque accru d'infections buccales.

The xerostomia therapeutics market refers to the commercial landscape related to the diagnosis, treatment, and management of dry mouth. It encompasses pharmaceutical companies, medical device manufacturers, and healthcare providers involved in the development and distribution of products and services aimed at addressing xerostomia. This market includes medications, saliva substitutes, oral moisturizers, chewing gums, mouthwashes, and other therapies or interventions designed to alleviate the symptoms and improve the quality of life for individuals with xerostomia.

Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • Rising Use of Chemotherapy and Radiotherapy in the Cancer Treatment

Radiation therapy to the head, face, or neck can cause dry mouth. It can take 6 months or longer after radiation therapy ends for the salivary glands to start producing saliva again. Dry mouth often improves during the first year after radiation treatment. But many people continue to have some level of long-term dry mouth. This is especially if the radiation therapy was directed at the salivary glands. Thus, the increasing adoption of chemotherapy and radiotherapy in cancer treatment is expected to drive market growth.

  • Growing Prevalence of Xerostomia

The prevalence of xerostomia is increasing due to the growing aging population. Age by itself is not a cause of xerostomia, but older patients tend to be on multiple medications and have a higher incidence of comorbid conditions. Thus, the growing prevalence of several diseases such as Sjogren’s syndrome, HIV, diabetes, and Alzheimer’s disease which ultimately leads to a rise in the number of patients suffering from xerostomia is expected to drive market growth.

  • Advancements in the Pharmaceutical Research and Development

The pharmaceutical sciences represent an evolving and highly dynamic field, and two overreaching trends show an increased effort to develop biologic-based drugs and create more specific or targeted drug delivery techniques. Advancements in pharmaceutical R&D have played a crucial role in improving healthcare outcomes, discovering new treatments, and enhancing patient care, which is expected to drive market growth.

Restraints

  • High Cost Associated with Xerostomia Treatment     

The products or devices which are used in the detection of xerostomia are becoming advanced but along with that the procedure for oral diseases diagnostics are also costly which hamper the market growth because the devices which are used in the process of cancer diagnosis getting more expensive which results to increase in the high cost of detection process of xerostomia. Thus, the high cost of xerostomia treatment is expected to restrain market growth. 

  • Side Effects Associated with Xerostomia Therapies

Xerostomia is one of the most common drug-related adverse effects in the oral cavity. Till date, more than 500 medications have been implicated in the etiology of xerostomia. The use of medications and advancing age are significant risk factors that cause xerostomia in elderly individuals. Thus, the side effects associated with xerostomia treatment are expected to restrain market growth.

Marché indien des traitements contre la xérostomie

Opportunities

  • Rising Product Collaborations and Partnerships

The market is promoted by the main market players involved in the development work with continuous research for the development of new drugs for xerostomia treatment with additional investments in the core market area. Players are working on product development that has advanced features to detect xerostomia in less time. If any diseases are detected at an early stage, it helps the patient to recover faster and prevent them from spreading to other parts of the body, which motivates market players in the development of new drugs. Increased product and drug collaborations and partnerships are expected to create opportunities for market growth.

  • Rising Research and Development Activities for the Development of Novel Therapies

The rise in the prevalence of chronic disease has generated interest and a burden on the research and healthcare department. Different manufacturing industries have taken a keen interest to develop new therapies for the treatment of chronic disease. There has been increased research activity regarding active pharmaceutical ingredients. Huge investment is done by the companies to develop novel products which will be used in the treatment of chronic diseases. So many products are under the developmental procedure for the treatment of different kinds of debilitating diseases, which is expected to create opportunities for market growth.

Challenges

  • Lack of Awareness of Xerostomia

The people in emerging countries suffer from several oral diseases more specifically periodontal disease followed by poverty, ignorance concerning health education, poor living conditions, lack of government funding, policy for providing good, and sufficient oral health care. The WHO and FDI are trying to identify these problems and come up with strategies for the improvement of such conditions.

  • Lack of Treatments Available for Xerostomia 

In today's complicated world, a disease diagnosis is a dynamic element that gives patients crucial knowledge for identifying, avoiding, treating, and controlling their diseases. The requirement for various therapies and treatments is rising with the increasing number of chronic diseases, which is expected to challenge market growth.

Recent Developments

  • In April 2023, 3M Health Information Systems announced a collaboration with Amazon Web Services (AWS) to accelerate the innovation and advancement of 3M M Modal ambient intelligence. As part of the collaboration, 3M will use AWS Machine Learning (ML) and generative AI services, including Amazon Bedrock, Amazon Comprehend Medical, and Amazon Transcribe Medical, to help expedite, refine, and scale the delivery of 3M's ambient clinical documentation and virtual assistant solutions. This has helped the company to expand its business.
  • In October 2022, Haleon Group of Companies invited consumer health startups in India, for the first time, to partner with Re/Wire Health Studio, a game-changing global collaboration and partnership platform from Haleon NEXT, the disruptive innovation arm of the global consumer health company Haleon. This has helped the company to expand its global presence.

India Xerostomia Therapeutics Market Scope

The India xerostomia therapeutics market is segmented into six notable segments based on product type, type, mode of purchase, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.  

Product Type

  • Saliva Substitutes
  • Drugs
  • Salivary Pen
  • Others

On the basis of product type, the market is segmented into saliva substitutes, drugs, salivary pen, and others.

Type

  • True Xerostomia
  • Pseudo Xerostomia or Symptomatic Xerostomia

On the basis of type, the market is segmented into true xerostomia and pseudo xerostomia or symptomatic xerostomia.

Mode of Purchase

  • Prescription (Rx)
  • Over the Counter (OTC)

On the basis of mode of purchase, the market is segmented into prescription (Rx) and Over the Counter (OTC).

Population Type

  • Geriatric
  • Adults

On the basis of population type, the market is segmented into geriatric and adults.

End User

  • Dental Clinics
  • Hospitals
  • Specialty Clinics
  • Home Care

On the basis of end user, the market is segmented into dental clinics, hospitals, specialty clinics, and home care.

Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Sales

On the basis of distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online sales.

Marché indien des traitements contre la xérostomie

Competitive Landscape and India Xerostomia Therapeutics Market Share Analysis

The India xerostomia therapeutics market is segmented into six notable segments based on product type, type, mode of purchase, population type, end user, and distribution channel.

Le paysage concurrentiel du marché indien des thérapies contre la xérostomie fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.

Certains des principaux acteurs du marché opérant sur le marché indien des thérapies contre la xérostomie sont Colgate-Palmolive Company, Sun Pharmaceutical Industries Ltd, Haleon Group of Companies, 3M, Alish Life Saving Impex Private Limited, GC Corporation, ICPA Health Products Ltd et Saliwell Ltd. entre autres.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE INDIA XEROSTOMIA THERAPEUTICS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 STAGES LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL'S MODEL

4.2 PORTER'S 5 FORCES

4.3 GROWTH STRATEGIES ADOPTED BY THE KEY MARKET PLAYERS

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS

7 INDIA XEROSTOMIA THERAPEUTICS MARKET, REGULATIONS

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING USE OF CHEMOTHERAPY AND RADIOTHERAPY IN THE CANCER TREATMENT

8.1.2 GROWING PREVALENCE OF XEROSTOMIA

8.1.3 ADVANCEMENTS IN THE PHARMACEUTICAL RESEARCH AND DEVELOPMENT

8.1.4 INCREASING USAGE OF PRESCRIPTION MEDICINES

8.2 RESTRAINTS

8.2.1 HIGH COST ASSOCIATED WITH XEROSTOMIA TREATMENT

8.2.2 SIDE EFFECTS ASSOCIATED WITH XEROSTOMIA THERAPIES

8.3 OPPORTUNITIES

8.3.1 RISING PRODUCT COLLABORATIONS AND PARTNERSHIPS

8.3.2 RISING RESEARCH AND DEVELOPMENT ACTIVITIES FOR THE DEVELOPMENT OF NOVEL THERAPIES

8.4 CHALLENGES

8.4.1 LACK OF AWARENESS OF XEROSTOMIA

8.4.2 LACK OF TREATMENTS AVAILABLE FOR XEROSTOMIA

9 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY PRODUCT TYPE

9.1 OVERVIEW

9.2 SALIVA SUBSTITUTES

9.2.1 MOUTHWASH

9.2.2 TOOTHPASTE

9.2.3 DENTIFRICES

9.2.4 ARTIFICIAL SALIVA

9.2.4.1 ORAL SOLUTION

9.2.4.1.1 ORAL SPRAY

9.2.4.1.2 ORAL RINSE

9.2.4.1.3 OTHERS

9.2.4.2 GEL

9.2.4.3 LOZENGE

9.2.4.4 DISSOLVING TABLETS

9.2.4.5 SWABS

9.2.4.6 POWDER

9.2.4.7 AQUORAL

9.2.4.8 SALIVASURE

9.2.4.9 OASIS

9.2.4.10 CAPHOSOL

9.2.4.11 XYLIMELTS

9.2.4.12 OTHERS

9.2.5 OIL-BASED SALIVA SUBSTITUTES

9.2.6 SALIVARY STIMULANTS

9.2.7 CHEWING GUMS

9.3 DRUGS

9.3.1 CHOLINOMIMETIC DRUGS

9.3.1.1 PILOCARPINE

9.3.1.2 CEVIMELINE

9.3.1.3 ANETHOLETRITHIONE

9.3.2 YOHIMBINE

9.3.3 OTHERS

9.3.4 BRANDED

9.3.5 SIALOR

9.3.6 PILOCARPINE

9.3.7 SALAGEN

9.3.8 EXOVAC

9.3.9 OTHERS

9.3.10 GENERIC

9.4 SALIVARY PEN

9.5 OTHER

10 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY TYPE

10.1 OVERVIEW

10.2 TRUE XEROSTOMIA

10.3 PSEUDO XEROSTOMIA OR SYMPTOMATIC XEROSTOMIA

11 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY MODE OF PURCHASE

11.1 OVERVIEW

11.2 PRESCRIPTION (RX)

11.3 OVER THE COUNTER (OTC)

12 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY POPULATION TYPE

12.1 OVERVIEW

12.2 GERIATRIC

12.3 ADULTS

13 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY END USER

13.1 OVERVIEW

13.2 DENTAL CLINICS

13.3 HOSPITALS

13.4 SPECIALTY CLINICS

13.5 HOME CARE

14 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 RETAIL PHARMACIES

14.3 HOSPITAL PHARMACIES

14.4 ONLINE SALES

15 INDIA XEROSTOMIA THERAPEUTICS MARKET: COMPANY LANDSCAPE

15.1 COMPANY SHARE ANALYSIS: INDIA

16 SWOT ANALYSIS

17 COMPANY PROFILE

17.1 COLGATE-PALMOLIVE COMPANY.

17.1.1 COMPANY SNAPSHOT

17.1.2 REVENUE ANALYSIS

17.1.3 PRODUCT PORTFOLIO

17.1.4 RECENT DEVELOPMENTS

17.2 SUN PHARMACEUTICAL INDUSTRIES LTD.

17.2.1 COMPANY SNAPSHOT

17.2.2 REVENUE ANALYSIS

17.2.3 PRODUCT PORTFOLIO

17.2.4 RECENT DEVELOPMENTS

17.3 HALEON GROUP OF COMPANIES.

17.3.1 COMPANY SNAPSHOT

17.3.2 REVENUE ANALYSIS

17.3.3 PRODUCT PORTFOLIO

17.3.4 RECENT DEVELOPMENTS

17.4 3M

17.4.1 COMPANY SNAPSHOT

17.4.2 REVENUE ANALYSIS

17.4.3 PRODUCT PORTFOLIO

17.4.4 RECENT DEVELOPMENTS

17.5 ALISH LIFE SAVING IMPEX PRIVATE LIMITED.

17.5.1 COMPANY SNAPSHOT

17.5.2 PRODUCT PORTFOLIO

17.5.3 RECENT DEVELOPMENT

17.6 GC CORPORATION.

17.6.1 COMPANY SNAPSHOT

17.6.2 PRODUCT PORTFOLIO

17.6.3 RECENT DEVELOPMENT

17.7 ICPA HEALTH PRODUCTS LTD

17.7.1 COMPANY SNAPSHOT

17.7.2 PRODUCT PORTFOLIO

17.7.3 RECENT DEVELOPMENT

17.8 SALIWELL LTD.

17.8.1 COMPANY SNAPSHOT

17.8.2 PRODUCT PORTFOLIO

17.8.3 RECENT DEVELOPMENT

18 QUESTIONNAIRE

19 RELATED REPORTS

Liste des tableaux

TABLE 1 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 2 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)

TABLE 3 INDIA SALIVA SUBSTITUTES IN XEROSTOMIA THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 4 INDIA SALIVA SUBSTITUTES IN XEROSTOMIA THERAPEUTICS MARKET, BY PRODUCT TYPE, 2021-2030 (VOLUME)

TABLE 5 INDIA ARTIFICIAL SALIVA IN XEROSTOMIA THERAPEUTICS MARKET, BY FORM, 2021-2030 (USD MILLION)

TABLE 6 INDIA ARTIFICIAL SALIVA IN XEROSTOMIA THERAPEUTICS MARKET, BY FORM, 2021-2030 (VOLUME)

TABLE 7 INDIA ORAL SOLUTION IN XEROSTOMIA THERAPEUTICS MARKET, BY FORM, 2021-2030 (USD MILLION)

TABLE 8 INDIA ORAL SOLUTION IN XEROSTOMIA THERAPEUTICS MARKET, BY FORM, 2021-2030 (VOLUME)

TABLE 9 INDIA ARTIFICIAL SALIVA IN XEROSTOMIA THERAPEUTICS MARKET, BY BRAND, 2021-2030 (USD MILLION)

TABLE 10 INDIA ARTIFICIAL SALIVA IN XEROSTOMIA THERAPEUTICS MARKET, BY BRAND, 2021-2030 (VOLUME)

TABLE 11 INDIA DRUGS IN XEROSTOMIA THERAPEUTICS MARKET, BY DRUG, 2021-2030 (USD MILLION)

TABLE 12 INDIA DRUGS IN XEROSTOMIA THERAPEUTICS MARKET, BY DRUG, 2021-2030 (VOLUME)

TABLE 13 INDIA CHOLINOMIMETIC DRUGS IN XEROSTOMIA THERAPEUTICS MARKET, BY DRUG, 2021-2030 (USD MILLION)

TABLE 14 INDIA CHOLINOMIMETIC DRUGS IN XEROSTOMIA THERAPEUTICS MARKET, BY DRUG, 2021-2030 (VOLUME)

TABLE 15 INDIA DRUGS IN XEROSTOMIA THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 16 INDIA BRANDED IN XEROSTOMIA THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 17 INDIA BRANDED IN XEROSTOMIA THERAPEUTICS MARKET, BY DRUG TYPE, 2021-2030 (VOLUME)

TABLE 18 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)

TABLE 19 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY MODE OF PURCHASE, 2021-2030 (USD MILLION)

TABLE 20 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY POPULATION TYPE, 2021-2030 (USD MILLION)

TABLE 21 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 22 INDIA XEROSTOMIA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Liste des figures

FIGURE 1 THE INDIA XEROSTOMIA THERAPEUTICS MARKET: SEGMENTATION

FIGURE 2 THE INDIA XEROSTOMIA THERAPEUTICS MARKET: DATA TRIANGULATION

FIGURE 3 THE INDIA XEROSTOMIA THERAPEUTICS MARKET: DROC ANALYSIS

FIGURE 4 THE INDIA XEROSTOMIA THERAPEUTICS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 THE INDIA XEROSTOMIA THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 THE INDIA XEROSTOMIA THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 THE INDIA XEROSTOMIA THERAPEUTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 THE INDIA XEROSTOMIA THERAPEUTICS MARKET: END USER COVERAGE GRID

FIGURE 9 THE INDIA XEROSTOMIA THERAPEUTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 THE INDIA XEROSTOMIA THERAPEUTICS MARKET: SEGMENTATION

FIGURE 11 THE RISING USE OF CHEMOTHERAPY AND RADIOTHERAPY IN THE CANCER TREATMENT IS EXPECTED TO DRIVE THE INDIA XEROSTOMIA THERAPEUTICS MARKET IN THE FORECAST PERIOD

FIGURE 12 PRODUCT TYPE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE INDIA XEROSTOMIA THERAPEUTICS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF INDIA XEROSTOMIA THERAPEUTICS MARKET

FIGURE 14 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY PRODUCT TYPE, 2022

FIGURE 15 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)

FIGURE 16 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)

FIGURE 17 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE

FIGURE 18 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY TYPE, 2022

FIGURE 19 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY TYPE, 2023-2030 (USD MILLION)

FIGURE 20 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 21 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY MODE OF PURCHASE ,2022

FIGURE 23 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY MODE OF PURCHASE, 2023-2030 (USD MILLION)

FIGURE 24 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY MODE OF PURCHASE , CAGR (2023-2030)

FIGURE 25 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY MODE OF PURCHASE , LIFELINE CURVE

FIGURE 26 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY POPULATION TYPE, 2022

FIGURE 27 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY POPULATION TYPE, 2023-2030 (USD MILLION)

FIGURE 28 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY POPULATION TYPE, CAGR (2023-2030)

FIGURE 29 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 30 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY END USER, 2022

FIGURE 31 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 32 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 35 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 36 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 37 INDIA XEROSTOMIA THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 INDIA XEROSTOMIA THERAPEUTICS MARKET: COMPANY SHARE 2022 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

The India xerostomia therapeutics market is anticipated to reach a value of USD 25.20 million by 2030, at a substantial CAGR of 5.1% during the forecast period.
The requirement for various therapies and treatments is rising with the increasing number of chronic diseases, which is expected to challenge market growth.
The major market players operating in the India xerostomia therapeutics market are Colgate-Palmolive Company., Sun Pharmaceutical Industries Ltd., Haleon Group of Companies., 3M., Alish Life Saving Impex Private Limited., GC Corporation, ICPA Health Products Ltd, and Saliwell Ltd.
The India xerostomia therapeutics market is segmented into six notable segments based on product type, type, mode of purchase, population type, end user, and distribution channel.
Increased product and drug collaborations and partnerships are expected to create opportunities for market growth.